Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatment of serious diseases with significant unmet medical needs in the orphan drug segment.

Emcitate® (tiratricol)

Our lead product candidate

Pipeline

Corporate presentation

Press Releases

Regulatory

April 3, 2025

NOTICE OF ANNUAL GENERAL MEETING IN EGETIS THERAPEUTICS AB (PUBL)

Read more

Regulatory

February 26, 2025

Year-End Report January-December 2024

Read more

February 25, 2025

Egetis Therapeutics to Host Virtual KOL Event to Discuss MCT8 Deficiency and Emcitate® (tiratricol) on March 4, 2025

Read more

Upcoming event

April 2, 2025

Van Lanschot Kempen Life Sciences Conference (Amsterdam)

Latest presentation

February 26, 2025

Year-end report 2024 (webcast)

Latest Report

February 26, 2025

Year-end report 2024

Calendar and upcoming reports

April 2, 2025

Van Lanschot Kempen Life Sciences Conference (Amsterdam)

April 30, 2025

Interim Report Q1 2025 (7:00am CEST)

May 6, 2025

Annual General Meeting

Joshua’s Story

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]